TrialsgrambetaRCTs are beautiful

PRODIGE 4 / ACCORD 11

2011

FOLFIRINOX in Metastatic Pancreatic Cancer

In 342 patients with metastatic pancreatic adenocarcinoma, ECOG 0–1, age ≤75, FOLFIRINOX improved overall survival compared with gemcitabine.

Result

Efficacy: Overall survivalHR 0.57

Below 1 favours FOLFIRINOX, above 1 favours gemcitabine.

Event rates FOLFIRINOX 11.1 vs gemcitabine 6.8 months

Also reported: PFS HR 0.47; ORR 31.6% vs 9.4%; more grade 3/4 toxicity but better QoL maintenance.

Original publication
Subtopic
Metastatic pancreatic
Design
Phase 2/3 RCT
Relevance
Important: one of several pillars.
Source
Conroy T, et al. N Engl J Med. 2011;364(19):1817-1825.doi 10.1056/NEJMoa1011923

Discussion & critique

Most active regimen in fit metastatic-pancreatic patients; later extended to the adjuvant setting (PRODIGE 24). Reserve for ECOG 0–1.